Texas Roundup: Pulmotect, Tech Wildcatters, Houston2035, & SynShark

Here’s the latest innovation news for Xconomy Texas.

Pulmotect, which is making an inhaled therapeutic to prevent and treat respiratory infections in cancer patients with compromised immune systems, received a $3 million grant from the National Institutes of Health. The Houston-based biotech company had previously received a $7.1 million matching award from the Cancer Prevention Research Institute of Texas in 2012. Phase 1b/2a clinical studies are expected to begin in late 2015 at the University of Texas MD Anderson Cancer Center. Pulmotect is part of Fannin Innovation Studio, a Houston accelerator/incubator of biotech companies.

Tech Wildcatters in Dallas held its annual pitch day last week at the American Airlines Center, home of the Dallas Stars and one of the founding members of the accelerator’s Corporate Innovation Network. The fifteen startups that pitched—Wildcatters’ largest class—specialize in innovations such as a flash-sale voucher that targets a restaurant’s slow hours, a mobile app that helps charity raise money through fundraising competitions at sporting events, and software that digitizes business processes like a time sheet app.

—The inaugural Houston 2035 conference brought together some of the city’s and nation’s top voices to discuss how the Bayou City could remain innovative in the decades to come. Among the topics discussed were entrepreneurship in biotech; cleantech; infrastructure and design; and edtech and IT.

—And here is the conference in pictures, and Storified.

Hired, a job recruitment website based in San Francisco, opened an Austin, TX, office. The site specializes in highly sought after engineers, data scientists, and other tech workers.

—My colleague Frank Vinluan in our Raleigh-Durham bureau has a great tale of a Texas A&M University spinout company named SynShark that says it’s invented a synthetic version of the chemical squalene, which is used in cosmetics and pharmaceutical production. Right now, the chemical is sourced from shark livers. The company is working on a method that would make squalene through genetically modified tobacco plants and could help to save three million sharks a year.

 

 

Author: Angela Shah

Angela Shah was formerly the editor of Xconomy Texas. She has written about startups along a wide entrepreneurial spectrum, from Silicon Valley transplants to Austin transforming a once-sleepy university town in the '90s tech boom to 20-something women defying cultural norms as they seek to build vital IT infrastructure in a war-torn Afghanistan. As a foreign correspondent based in Dubai, her work appeared in The New York Times, TIME, Newsweek/Daily Beast and Forbes Asia. Before moving overseas, Shah was a staff writer and columnist with The Dallas Morning News and the Austin American-Statesman. She has a Bachelor's of Journalism from the University of Texas at Austin, and she is a 2007 Knight-Wallace Fellow at the University of Michigan. With the launch of Xconomy Texas, she's returned to her hometown of Houston.